The following adverse reactions are discussed in greater detail in other sections of the labeling: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice
Dyspepsia specifically is listed as a common side effect (affecting between 1 in 10 and 1 in 100 people)
3.3.4 Polyethylene glycol loxenatide The early GLP-1R agonist has many defects, such as multiple injections and a high incidence of adverse reactions in the digestive tract, which limits its clinical application
Lanzan en la Argentina un medicamento inyectable nacional contra la obesidad La nueva formulacin del laboratorio Elea irrumpe en un mercado marcado por precios elevados y una demanda en crecimiento 5 minutos de lectura' El laboratorio Elea anunci el lanzamiento de la primera semaglutida de produccin nacional aprobada para el tratamiento del sobrepeso y la obesidad , en un contexto en el que los agonistas del receptor GLP-1 se han convertido en uno de los desarrollos farmacolgicos ms disruptivos de los ltimos aos
All of the test subjects included in the study were randomly assigned to 1 of 10 different experimental treatment groups
10.1016/j.cbpa.2021.01.006 182 ShindoH.Harada-ShojiN.EbataA.SatoM.SogaT.MiyashitaM.et al (2021)
